Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.96 +0.09 (+0.35%)
Official Closing Price Updated: 7:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Valneva Q1 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme... 
Via MarketBeat
Topics Earnings
News headline image
These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for... 
Via Benzinga
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
3 Struggling Stocks That Could Make for Great Contrarian Buys ↗
These stocks are facing some headwinds, but they may prove to be big winners in the long run. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
From Pfizer Inc.
Via Business Wire
News headline image
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call
Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Manag... 
Via StockStory
Topics Earnings
News headline image
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer ↗
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval. 
Via Benzinga
News headline image
Prediction: Pfizer Will Beat the Market Over the Next 5 Years ↗
It's a great time to "buy low." 
Via The Motley Fool
Topics Intellectual Property
News headline image
Up 373%, Is ExxonMobil Proving Why It Was a Mistake for Salesforce to Replace ExxonMobil in the Dow Jones Industrial Average? ↗
The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks. 
Via The Motley Fool
Topics Stocks
News headline image
Arvinas Q1 Earnings Call Highlights ↗
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline... 
Via MarketBeat
Topics Earnings
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Is Pfizer a Buy, Sell, or Hold in 2026? ↗
Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe? ↗
At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable. 
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call
Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launc... 
Via StockStory
Topics Earnings
News headline image
Is This a Sign Pfizer's Aggressive Growth Strategy Is Paying Off? ↗
Pfizer's acquired and recently launched products generated strong growth last quarter. 
Via The Motley Fool
Topics Intellectual Property
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers? ↗
Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Healthcare Stocks Every Retiree Should Consider ↗
If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Got $5,000 to Invest in a Volatile Market? Here's Exactly Where I'd Put It. ↗
Look for names that tend to trade independently of the overall market, and don't be afraid to achieve some income growth. 
Via The Motley Fool
Topics Economy
What Are Horizontal Mergers and Acquisitions?
Via BusinesNews Wire
Topics Economy
News headline image
GoodRx (GDRX) Q1 2026 Earnings Call Transcript ↗
GoodRx (GDRX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. ↗
The competition is far behind. 
Via The Motley Fool
News headline image
Forget Eli Lilly: These 2 Stocks Have More Upside ↗
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors. 
Via The Motley Fool
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
Zoetis (NYSE:ZTS) Misses Q1 CY2026 Revenue Estimates, Stock Drops 13%
Animal health company Zoetis (NYSE:ZTS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales only rose 1.9% year on year to $2.26 billion. The com... 
Via StockStory
News headline image
Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue
Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.